UBS Reiterates Neutral, $220 PT on iPhone 17 Availability Data

Apple Inc. (Nasdaq:AaplHe is one of Amnesty International’s Stocks are in the spotlight this week. On September 24, an UBS David Vogt analyst repeated a neutral rating and a $ 220.00 goal on the arrow. The classification confirmation follows an iPhone 17 data analysis via 30 global markets.

Based on UBS Laboratory data, waiting times appear high for the primary but silent iPhone 17 model. The company believes that there are high risks on iPhone built with iPhone 17 and air variables. This is in line with modern reports that Apple suppliers increase the production of the basic model.

Meanwhile, waiting times for Pro and Pro Max are compatible with China with last year, while air models are flat down compared to 16 Plus.

According to the company, the transition to novice phone models may limit the average sale price in the quarter of September. The waiting times will be a major measure, as they are settled or shortened at this time last year.

UBS Laboratory data (> access data data) that tracks iPhone is proposed across 30 geographically high waiting times in the markets across the main markets, but relatively silent demand for the other three models. We believe that the data is consistent with our presence in our main offer to adapt, and leads to an increase in the risks We note that it started to settle or neglect at this time last year depending on the model and geography.

Apple is a technology company known for its electronics, programs and consumer services.

While we acknowledge the capabilities of AAPL as an investment, we believe that some artificial intelligence shares provide greater potential in the upward trend and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.